Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 68.2827
- Book/Share 31.2062
- PB 9.8739
- Debt/Equity 0.857
- CurrentRatio 0.7386
- ROIC 0.3875
- MktCap 1475022984970.3071
- FreeCF/Share 16.8361
- PFCF 19.7343
- PE 13.0759
- Debt/Assets 0.2427
- DivYield 0.0342
- ROE 0.8124
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies
Published: May 14, 2025 by: Proactive Investors
Sentiment: Positive
Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targeting obesity and other cardiometabolic diseases. The partnership brings together Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery with Nono Nordisk's established obesity and metabolic disease therapies, which include the injectables Wegovy and Ozempic.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Novo Nordisk: Is obesity wonder drug Wegovy losing its investment appeal?
Published: May 12, 2025 by: Proactive Investors
Sentiment: Neutral
Private investors considering Novo Nordisk (NYSE:NVO) should approach with measured optimism. The Danish drugmaker is a global leader in the fast-growing obesity market, but Morgan Stanley believes the near-term outlook is mixed.
Read More
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial
Published: May 12, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the first head-to-head comparison between the two leading obesity treatments. In the 72-week SURMOUNT-5 trial, participants on Zepbound lost an average of about 50 pounds (22.8 kg), equating to approximately 20.2% of their body weight.
Read More
Novo Nordisk Stock Is Slumping Today. Here's Why.
Published: May 12, 2025 by: Barrons
Sentiment: Negative
Shares of the Ozempic-maker fell while the rest of the market rose,as it's facing a hit to revenue from different directions.
Read More
Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Positive
Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug announcement caused undue panic; NVO's advanced pipeline, including oral semaglutide and Amycretin, remains highly competitive. The partnership with Hims & Hers mitigates legal risks and boosts distribution, promising significant synergies and long-term benefits for the Company.
Read More
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 12 May 2025 – Novo Nordisk today presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya® (somapacitan) was non-inferior to the once-daily growth hormone Norditropin® (somatropin) in improving yearly growth rate (as measured by height velocity [HV] at Week 52) in pre-pubertal children born small for gestational age (SGA)1, or with Noonan syndrome (NS)2, or with idiopathic short stature (ISS)3. In addition, superiority was achieved for once-weekly Sogroya® versus daily growth hormone in children with NS2, as well as compared to lower doses of daily growth hormone in children born SGA1.
Read More
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Published: May 11, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Read More
Novo Nordisk: It's Not Been This Cheap For Many Years
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Despite setbacks, Novo is actively enhancing market access for Wegovy and partnering with CVS and telehealth platforms to regain momentum. NVO's valuation is at a multi-year low, pointing to a plausible recovery if it manages to improve its execution and stem further losses.
Read More
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Read More
Novo Nordisk (NVO) Upgraded to Buy: Here's What You Should Know
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Novo Nordisk (NVO) is a Top Dividend Stock Right Now: Should You Buy?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Does Novo Nordisk (NVO) Have the Potential to Rally 51.24% as Wall Street Analysts Expect?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 51.2% upside potential for Novo Nordisk (NVO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers
Published: May 08, 2025 by: Fast Company
Sentiment: Positive
One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk's outlook is brightening.
Read More
GLP-1 competition heats up: Novo Nordisk CEO talks Wegovy, CVS deal, earnings
Published: May 07, 2025 by: Yahoo Finance
Sentiment: Positive
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94).
Read More
Novo Nordisk A/S (NVO) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S (NVO) Q1 2025 Results Conference Call May 7, 2025 7:00 AM ET Company Participants Jacob Rode - Head of Investor Relations Lars Jorgensen - President and Chief Executive Officer David Moore - Executive Vice President, U.S. Operations and Global Business Development Mike Doustdar - Executive VP of International Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Richard Vosser - JPMorgan Chase & Co. James Quigley - Goldman Sachs Peter Verdault - BNP Paribas Martin Parkhoi - SEB Michael Nedelcovych …
Read More
Why Novo Nordisk Stock Popped After Earnings
Published: May 07, 2025 by: The Motley Fool
Sentiment: Positive
GLP-1 drugmaker Novo Nordisk's (NVO 2.01%) stock jumped at the open and remains up 3.2% as of 10:20 a.m. ET after the company reported earnings this morning.
Read More
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
Read More
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with diluted EPS up 15% year-on-year. ~65% of revenues were driven by semaglutide, or Wegovy (obesity)/Ozempic (diabetes). This is truly a miraculous drug, and as compounded versions of semaglutide cease to be manufactured, performance will improve in 2H25.
Read More
SMCI Miss "Across the Board," NVO Wegovy Sales Up 85%, ANET Down on Beat
Published: May 07, 2025 by: Schwab Network
Sentiment: Negative
Diane King Hall discusses the biggest earnings movers this morning, including Novo Nordisk (NVO), which saw a 85% year-over-year increase in Wegovy sales but still trimmed guidance. Supermicro (SMCI) "missed across the board" in its earnings and trimmed guidance.
Read More
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Published: May 07, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Read More
Novo Nordisk investors relieved after expected guidance cut
Published: May 07, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) first-quarter results offered few surprises, but they may just have delivered the market something it needed more: relief. That collective anxiety release was reflected in the share price, which rose 4%.
Read More
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump.
Published: May 07, 2025 by: Investors Business Daily
Sentiment: Negative
Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due what Novo says is illegal compounding of GLP-1 medicines.
Read More
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive
Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise, defying the 55% stock drop. Novo Nordisk's profitability and growth in emerging markets, coupled with a forward P/E ratio of 16.35x, make it an undervalued investment opportunity. Market concerns over minor market share losses are overblown; NVO remains the leader in a rapidly growing obesity and diabetes market.
Read More
Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut
Published: May 07, 2025 by: Investopedia
Sentiment: Neutral
U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.
Read More
Novo Nordisk CEO says 'compounders took a part of our business away'
Published: May 07, 2025 by: CNBC International TV
Sentiment: Neutral
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in on the impact of compounded drugs on first-quarter Wegovy sales while forecasting a rebound later this year.
Read More
Drugmaker Novo Nordisk drops gender representation requirements in the US
Published: May 07, 2025 by: Reuters
Sentiment: Neutral
Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for its U.S. business following executive orders by President Donald Trump to stop diversity, equity and inclusion initiatives.
Read More
Novo Nordisk shares are rising after the company cut its outlook. It's been that kind of year.
Published: May 07, 2025 by: Market Watch
Sentiment: Neutral
Novo Nordisk is managing the unusual feat of seeing its stock price rise after reducing its earnings outlook.
Read More
Novo Nordisk shares rise despite cut to 2025 outlook
Published: May 07, 2025 by: Proactive Investors
Sentiment: Positive
Investors breathed a sigh of relief on Wednesday as shares in Novo Nordisk (NYSE:NVO) rose 3% in early trading, despite the drugmaker trimming its sales and profit forecasts for 2025. The downgrade, which had largely been anticipated, brings an end to a four-year streak of upgrades driven by booming demand for its obesity drug Wegovy.
Read More
Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales
Published: May 07, 2025 by: WSJ
Sentiment: Negative
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, particularly in the U.S.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406